| Why carry out this study? |
| Fosnetupitant can be used prophylactically as an antiemetic for chemotherapy-induced nausea and vomiting (CINV); however, its longer-term efficacy needs to be confirmed. |
| The risk factors for CINV up to 168 h after chemotherapy administration are unclear. |
| What was learned from this study? |
| The complete response rate was significantly better with fosnetupitant compared with fosaprepitant. |
| Treatment failure in the first 120 h after chemotherapy administration was a risk factor for CINV. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.